Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Chimeric antigen receptor-engineered T cells as oncolytic virus carriers.

VanSeggelen H, Tantalo DG, Afsahi A, Hammill JA, Bramson JL.

Mol Ther Oncolytics. 2015 Sep 9;2:15014. doi: 10.1038/mto.2015.14.

2.

Stem Cell-Based Cell Carrier for Targeted Oncolytic Virotherapy: Translational Opportunity and Open Questions.

Kim J, Hall RR, Lesniak MS, Ahmed AU.

Viruses. 2015 Nov 27;7(12):6200-17. doi: 10.3390/v7122921. Review.

3.

Cytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognition.

Wei F, Rong XX, Xie RY, Jia LT, Wang HY, Qin YJ, Chen L, Shen HF, Lin XL, Yang J, Yang S, Hao WC, Chen Y, Xiao SJ, Zhou HR, Lin TY, Chen YS, Sun Y, Yao KT, Xiao D.

Oncotarget. 2015 Oct 27;6(33):35023-39. doi: 10.18632/oncotarget.5280.

4.

Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.

Rojas JJ, Sampath P, Hou W, Thorne SH.

Clin Cancer Res. 2015 Dec 15;21(24):5543-51. doi: 10.1158/1078-0432.CCR-14-2009.

5.

Cancer stem cells in breast cancer.

Takahashi RU, Takeshita F, Fujiwara T, Ono M, Ochiya T.

Cancers (Basel). 2011 Mar 15;3(1):1311-28. doi: 10.3390/cancers3011311.

6.

Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites.

Jennings VA, Ilett EJ, Scott KJ, West EJ, Vile R, Pandha H, Harrington K, Young A, Hall GD, Coffey M, Selby P, Errington-Mais F, Melcher AA.

Int J Cancer. 2014 Mar 1;134(5):1091-101. doi: 10.1002/ijc.28450.

7.

Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.

Sampath P, Li J, Hou W, Chen H, Bartlett DL, Thorne SH.

Mol Ther. 2013 Mar;21(3):620-8. doi: 10.1038/mt.2012.257.

8.

Evaluation of monocytes as carriers for armed oncolytic adenoviruses in murine and Syrian hamster models of cancer.

Bunuales M, Garcia-Aragoncillo E, Casado R, Quetglas JI, Hervas-Stubbs S, Bortolanza S, Benavides-Vallve C, Ortiz-de-Solorzano C, Prieto J, Hernandez-Alcoceba R.

Hum Gene Ther. 2012 Dec;23(12):1258-68. doi: 10.1089/hum.2012.043.

9.

Theranostic potential of oncolytic vaccinia virus.

Rojas JJ, Thorne SH.

Theranostics. 2012;2(4):363-73. doi: 10.7150/thno.3724.

10.

The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon.

Alvarez-Breckenridge CA, Yu J, Price R, Wei M, Wang Y, Nowicki MO, Ha YP, Bergin S, Hwang C, Fernandez SA, Kaur B, Caligiuri MA, Chiocca EA.

J Virol. 2012 Apr;86(8):4566-77. doi: 10.1128/JVI.05545-11.

11.

Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity.

Wang LC, Lynn RC, Cheng G, Alexander E, Kapoor V, Moon EK, Sun J, Fridlender ZG, Isaacs SN, Thorne SH, Albelda SM.

Mol Ther. 2012 Apr;20(4):736-48. doi: 10.1038/mt.2011.228.

12.

Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors.

Yu D, Jin C, Leja J, Majdalani N, Nilsson B, Eriksson F, Essand M.

J Virol. 2011 Dec;85(24):13114-23. doi: 10.1128/JVI.05759-11.

13.

Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer.

Huang B, Sikorski R, Sampath P, Thorne SH.

J Immunother. 2011 Apr;34(3):289-96. doi: 10.1097/CJI.0b013e31820e1b0d.

14.

Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.

Li J, O'Malley M, Urban J, Sampath P, Guo ZS, Kalinski P, Thorne SH, Bartlett DL.

Mol Ther. 2011 Apr;19(4):650-7. doi: 10.1038/mt.2010.312.

Items per page

Supplemental Content

Support Center